Pfizer has pledged a shipment of its experimental antiviral COVID-19 pill to Israel, according to a Saturday television report, a week after the US drugmaker said it was engaged in “active discussion” with 90 countries regarding the coronavirus medication.
Prime Minister Naftali Bennett and Health Minister Nitzan Horowitz reached an agreement with the drug company for tens of thousands of doses, Channel 12 news reported. The shipment will be despatched as soon as Pfizer receives FDA approval for the pill, the TV report said.
The report comes as Bennett said last week Israel was looking into purchasing the new pill.
Israel’s successful coronavirus vaccination campaign was largely the result of clinching the first contracts with Pfizer-BioNTech for the mass supply of the immunizations late last year. With Israel’s high vaccination rates, however, it remains unclear how pressing the immediate need is for the COVID medication.
Last week, Pfizer released preliminary results of its pill study of 775 adults. Patients taking the company’s drug along with another antiviral had an 89% reduction in their combined rate of hospitalization or death after a month, compared to patients taking a dummy pill. Fewer than 1% of patients taking the drug needed to be hospitalized and no one died. In the comparison group, 7% were hospitalized and there were seven deaths.
Pfizer CEO Albert Bourla said some countries have already signed contracts for the medication. “We are in discussions with 90 governments around the world right now, active discussion, and some of them already signed,” Bourla said last Friday. At that stage, Israel was reported to not be among the countries in talks with Pfizer on buying the pills.
Currently, all COVID-19 treatments used in the US require an IV or injection. Competitor Merck’s COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and earlier this month the United Kingdom became the first country to OK it.
Pfizer said it will ask the FDA and international regulators to authorize its pill as soon as possible, after independent experts recommended halting the company’s study based on the strength of its results. Once Pfizer applies, the FDA could make a decision within weeks or months.
Researchers worldwide have been racing to find a pill against COVID-19 that can be taken at home to ease symptoms, speed recovery, and reduce the crushing burden on hospitals and doctors.
“We were hoping that we had something extraordinary, but it’s rare that you see great drugs come through with almost 90% efficacy and 100% protection for death,” said Dr. Mikael Dolsten, Pfizer’s chief scientific officer, in an interview.
Study participants were unvaccinated, with mild-to-moderate COVID-19, and were considered high risk for hospitalization due to health problems like obesity, diabetes or heart disease. Treatment began within three to five days of initial symptoms, and lasted for five days.
Pfizer reported few details on side effects but said rates of problems were similar between the groups at about 20%.
An independent group of medical experts monitoring the trial recommended stopping it early, standard procedure when interim results show such a clear benefit. The data have not yet been published for outside review, the normal process for vetting new medical research.
Top US health officials continue to stress that vaccination will remain the best way to protect against infection. But with tens of millions of adults still unvaccinated — and many more globally — effective, easy-to-use treatments will be critical to curbing future waves of infections.
The FDA has set a public meeting later this month to review Merck’s pill, known as molnupiravir. The company reported in September that its drug cut rates of hospitalization and death by 50%. Experts warn against comparing preliminary results because of differences in studies.
Although Merck’s pill is further along in the US regulatory process, Pfizer’s drug could benefit from a safety profile that is more familiar to regulators with fewer red flags. While pregnant women were excluded from the Merck trial due to a potential risk of birth defects, Pfizer’s drug did not have any similar restrictions. The Merck drug works by interfering with the coronavirus’ genetic code, a novel approach to disrupting the virus.
Pfizer’s drug is part of a decades-old family of antiviral drugs known as protease inhibitors, which revolutionized the treatment of HIV and hepatitis C. The drugs block a key enzyme that viruses need to multiply in the human body.
The drug, which has not yet been named, was first identified during the SARS outbreak originating in Asia in 2003. Last year, company researchers decided to revive the medication and study it for COVID-19, given the similarities between the two coronaviruses.
The US has approved one other antiviral drug for COVID-19, remdesivir, and authorized three antibody therapies that help the immune system fight the virus. But they have to be given by IV or injection at hospitals or clinics, and limited supplies were strained by the last surge of the delta variant.
What’s Hebrew for ‘fierce’?
In Streetwise Hebrew for the Times of Israel Community, each month we learn several colloquial Hebrew phrases around a common theme. These are bite-size audio Hebrew classes that we think you’ll really enjoy.
This month, we’re learning phrases on the topic of strength and power. Ready to get tough with us?
You’re serious. We appreciate that!
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we come to work every day – to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.